Home › Research › Brain tissue and pathology
Putaminal hypermetabolism identifies Lewy body co-pathology in Alzheimer's disease
Sungwoo Kang, Seun Jeon, Yeoju Kim, Su-Hee Jeon, Minsun Choi, Young-Gun Lee, Byoung Seok Ye, Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-11
Topic: Plasma and spinal-fluid biomarkers
Compared to ADSAA-, ADSAA+ showed putamen SRP hypermetabolism and middle occipital gyrus (MOG) SUVR hypometabolism. SAA positivity correlated with putamen SRP hypermetabolism independently of pTau181/amyloid beta 42 (Aβ42). Its interaction with pTau181/Aβ42 influenced MOG SUVR, showing increased MOG SUVR with higher pTau181/Aβ42 in ADSAA+. Putamen SRP hypermetabolism predicted faster cognitive decline and greater variability in both groups. MOG SUVR hypometabolism correlated with them only in ADSAA-. Adding putamen SRP hypermetabolism to models, including SAA positivity and AD signature hypometabolism, improved the prediction of cognitive decline/variability, whereas MOG SUVR did not. Putaminal hypermetabolism may serve as a robust metabolic marker of LBD co-pathology in AD. HIGHLIGHTS: LB co-pathology in AD alters regional brain metabolism. SRP analyses capture putaminal hypermetabolism for SAA positivity. SUVR analyses emphasize occipital hypometabolism for SAA positivity. Occipital metabolism correlates positively with AD severity in mixed AD-LB. Putaminal, not occipital, metabolism predicts cognitive change over AD-related metabolism and SAA.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kang, S., Jeon, S., Kim, Y., Jeon, S.-H., Choi, M., Lee, Y.-G., et al. (2025). Putaminal hypermetabolism identifies Lewy body co-pathology in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70920
Vancouver
Kang S, Jeon S, Kim Y, Jeon S.-H, Choi M, Lee Y.-G, et al. Putaminal hypermetabolism identifies Lewy body co-pathology in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70920. PMID: 41273227.
BibTeX
@article{kang2025-41273227,
author = {Kang, Sungwoo and Jeon, Seun and Kim, Yeoju and Jeon, Su-Hee and Choi, Minsun and Lee, Young-Gun and Ye, Byoung Seok and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{Putaminal hypermetabolism identifies Lewy body co-pathology in Alzheimer's disease}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70920},
pmid = {41273227},
url = {https://doi.org/10.1002/alz.70920}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Compared to ADSAA-, ADSAA+ showed putamen SRP hypermetabolism and middle occipital gyrus (MOG) SUVR hypometabolism.
- SAA positivity correlated with putamen SRP hypermetabolism independently of pTau181/amyloid beta 42 (Aβ42).
- Its interaction with pTau181/Aβ42 influenced MOG SUVR, showing increased MOG SUVR with higher pTau181/Aβ42 in ADSAA+.
- Putamen SRP hypermetabolism predicted faster cognitive decline and greater variability in both groups.
- MOG SUVR hypometabolism correlated with them only in ADSAA-.
Study details
- Evidence strengthLow
How this study scored 46/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 26 of the 56 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41273227) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 26 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 26 of the 56 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Brain tissue and pathology
Also tagged “diffusion”
171 studies in the library carry the topic tag “diffusion”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 171 tagged studies.